- Home
- GLTO vs VERO Comparison
GLTO vs VERO Comparison
Compare GLTO & VERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- VERO
- Stock Information
- Founded
- GLTO 2011
- VERO N/A
- Country
- GLTO Denmark
- VERO Canada
- Employees
- GLTO N/A
- VERO N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- VERO Medical/Dental Instruments
- Sector
- GLTO Health Care
- VERO Health Care
- Exchange
- GLTO Nasdaq
- VERO Nasdaq
- Market Cap
- GLTO 4.5M
- VERO 4.6M
- IPO Year
- GLTO 2020
- VERO N/A
- Fundamental
- Price
- GLTO $3.54
- VERO $2.69
- Analyst Decision
- GLTO Buy
- VERO
- Analyst Count
- GLTO 1
- VERO 0
- Target Price
- GLTO $10.00
- VERO N/A
- AVG Volume (30 Days)
- GLTO 13.7K
- VERO 1.1M
- Earning Date
- GLTO 08-11-2025
- VERO 08-12-2025
- Dividend Yield
- GLTO N/A
- VERO N/A
- EPS Growth
- GLTO N/A
- VERO N/A
- EPS
- GLTO N/A
- VERO N/A
- Revenue
- GLTO N/A
- VERO $60,997,000.00
- Revenue This Year
- GLTO N/A
- VERO N/A
- Revenue Next Year
- GLTO N/A
- VERO $7.47
- P/E Ratio
- GLTO N/A
- VERO N/A
- Revenue Growth
- GLTO N/A
- VERO N/A
- 52 Week Low
- GLTO $2.01
- VERO $2.10
- 52 Week High
- GLTO $16.07
- VERO $14.50
- Technical
- Relative Strength Index (RSI)
- GLTO 59.96
- VERO 54.13
- Support Level
- GLTO $3.24
- VERO $2.61
- Resistance Level
- GLTO $3.60
- VERO $3.09
- Average True Range (ATR)
- GLTO 0.26
- VERO 0.25
- MACD
- GLTO -0.01
- VERO 0.04
- Stochastic Oscillator
- GLTO 60.98
- VERO 58.51
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.